SELLAS Life Sciences Group, Inc (NASDAQ:SLS)
| Market Cap | $1.73B+472.0% |
| Revenue (ttm) | $0 |
| Net Income | -$32.46M-23.6% |
| EPS | -$0.21+35.4% |
| Shares Out | 201.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,762,805 |
| Open | $8.16 |
| Previous Close | $8.42 |
| Day's Range | $7.89 - $8.87 |
| 52-Week Range | $1.39 - $15.88 |
| Beta | 2.70 |
| Analysts | Buy |
| Price Target | $35.00(+307.93%) |
| Earnings Date | Nov 18, 2026 |
About SLS
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SLS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SLS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SLS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SLS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SLS Revenue by Segment
| Future milestone payments received | $194.50M | 48.14% |
| Potential milestone payments to be received | $191.50M | 47.40% |
| Licensing revenue | $10.50M | 2.60% |
| Upfront cash payment received | $7.50M | 1.86% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SLS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SLS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SLS
| XBIState Street SPDR S&P Biotech ETF | $49.50M |
| IWMiShares Russell 2000 ETF | $43.89M |
| VXFVanguard Extended Market ETF | $28.06M |
| IWOiShares Russell 2000 Growth ETF | $16.06M |
| VTWOVanguard Russell 2000 ETF | $14.39M |
| SCHASchwab U.S. Small-Cap ETF | $9.08M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SLS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive Phase 2 AML data and upcoming Q4 results drive optimism, though stock volatility and analyst stake cuts create mixed near-term signals.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 1.06% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.79% |
| ETHO | Amplify Etho Climate Leadership U.S. ETF | 0.56% |
| XBI | State Street SPDR S&P Biotech ETF | 0.46% |
| IWC | iShares Micro-Cap ETF | 0.42% |
| AFSM | First Trust Active Factor Small Cap ETF | 0.32% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.19% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.16% |
| VMO.TO | Vanguard Global Momentum Factor ETF | 0.15% |
| IWO | iShares Russell 2000 Growth ETF | 0.11% |
| USVM | VictoryShares US Small Mid Cap Value Momentum ETF | 0.10% |
| PWS | Pacer WealthShield ETF | 0.09% |
Weight is the stock’s share of each fund’s holdings.
